Gelatinolytic activities (matrix metalloproteinase-2 and -9) and soluble extracellular domain of HER-2/neu in pleural effusions

Oncology Reports

Volumn 18, Issue 2, 2007, Pages 425-431

  Di Carlo, Angelina ^a   Mariano, Angela ^b   Terracciano, Daniela ^b   Mazzarella, Claudia ^b   Galzerano, Sonia ^b   Cicalese, Marcellino ^b   Cecere, Ciriaco ^b   Macchia, Vincenzo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Pleural effusions; Soluble extracellular domain of HER 2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATIN; GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; BINDING SITE; BREAST TUMOR; COLON TUMOR; ENZYMOLOGY; FEMALE; FIBROSIS; HUMAN; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; PLEURA EFFUSION; PLEURISY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROGNOSIS; SOLUBILITY;

ADULT; AGED; BINDING SITES; BREAST NEOPLASMS; COLONIC NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FIBROSIS; GELATIN; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OVARIAN NEOPLASMS; PLEURAL EFFUSION; PLEURISY; PROGNOSIS; RECEPTOR, ERBB-2; SOLUBILITY;

EID: 34548544721     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.2.425     Document Type: Article

References (35)

1. Banerjee AK, Willetts I, Robertson JF and Blamey RW: Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 20: 33-36, 1994. (Pubitemid 24104946)
2. Dieterich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D and Sherman ME: Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 38: 945-952, 1994.
3. Fenton KN and Richardson JD: Diagnosis and management of malignant pleural effusions: Am J Surg 170: 69-74, 1995.
4. Bedrossian CW: Diagnostic problems in serous effusions. Diagn Cytopathol 19: 131-137, 1998.
5. Porcel JM and Light RW: Diagnostic approach to pleural effusion in adults. Am Fam Physician 73: 1211-1229, 2006.
6. Neragi-Miandoab S: Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54: 1-9, 2006.
7. Terracciano D, Di Carlo A, Papa P, Cicalese M, Maietta P, Cecere C, Mariano A and Macchia V: New approaches in the diagnostic procedure of malignant pleural effusion. Oncol Rep 12: 79-83, 2004.
8. Porcel JM, Vives M, Esquerda A, Salud A, Perez B and Rodriguez-Panadero F: Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 126: 1757-1763, 2004. (Pubitemid 39643976)
9. Light RW: Tumor markers in undiagnosed pleural effusions. Chest 126: 1721-1722, 2004.
10. Shitrit D, Zingerman B, Bar-Gil Shitrit A, Shlomi D and Kramer MR: Diagnostic value of Cyfra 21-1, CEA, CA19-9, CA 15-3 and CA125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 10: 501-507, 2005. (Pubitemid 41266331)
11. Ghayumi SMA, Mehrabi S, Doroudchi M and Ghaderi A: Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res 11: 236-241, 2005. (Pubitemid 43266927)
12. Aaronson SA: Growth factor and cancer. Science 254: 1146-1153, 1991.
13. Hynes NE and Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994.
14. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
15. Di Carlo A, Terracciano D, Mariano A and Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenase in serum of patients with pleural effusions. Int J Oncol 26: 1363-1368, 2005.
16. Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755: 37-69, 2005. (Pubitemid 40720240)
17. Giunciuglio D, Culty M, Fassina G, Masiello L, Melchiori A, Paglialunga G, Arand G, Ciardiello F, Basolo F, Thompson EW and Albini A: Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 63: 815-822, 1995.
18. Kaya M, Yoshida K, Higashino F, Mitaka T, Ishii S and Fujinaga K: A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 12: 221-227, 1996. (Pubitemid 26042559)
19. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demeres L, Podczaski E, Harvey H, Shambaugh S and Volas G: Elevated soluble c-erbB-2 antigen levels in the serum effusions of a preparation of breast cancer patients. J Clin Oncol 10: 436-443, 1992.
20. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G and Colnaghi MI: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923, 1993. (Pubitemid 23312894)
21. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J: Cleavage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of matrix-metalloproteinase-1 in breast cancer cells. Cancer Res 59: 1196-1201, 1999. (Pubitemid 29136246)
22. Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
23. Di Carlo A, Terracciano D, Mariano A and Macchia V: Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep 15: 1321-1326, 2006.
24. Light RW: Clinical practice. Pleural effusion. N Engl J Med 346: 1971-1977, 2002.
25. Triebel S, Blaser J, Reinke H and Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314: 386-388, 1992. (Pubitemid 23005695)
26. Yan L, Borregaard N, Kjeldsen L and Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP and neutrophil gelatinase-associated lipocalin (NGAL). J Biol Chem 276: 37258-37265, 2001.
27. Goldberg GI, Strongin A, Collier IE, Genrich LT and Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of proenzyme with stromelysin. J Biol Chem 267: 4583-4591, 1992.
28. Rundhaug JE: The biology behind matrix metalloproteinases, angiogenesis and cancer. Clin Cancer Res 9: 551-554, 2003.
29. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J and Baselga J: Trastuzumb (Herceptin), a humanized anti-HER-2/neu receptor monoclonal antibody inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749, 2001. (Pubitemid 32691885)
30. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S and Price CP: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49: 1579-1598, 2003. (Pubitemid 37194212)
31. Hung TL, Chen FF, Liu JM, Lai WW, Hsiao AL, Huang WT, Chen HHW and Su WC: Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. Clin Cancer Res 9: 2605-2612, 2003. (Pubitemid 36842103)
32. Kotyza J, Pesek M, Bednárova V, Terl M and Werle B: Pleural fluids associated with metastatic lung tumors are rich in progelatinase B/proMMP-9. Neoplasma 52: 388-392, 2005. (Pubitemid 41406686)
33. Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Trope CG, Bryne M, Kopolovic J and Nesland JM: Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37: 2040-2049, 2001. (Pubitemid 32938107)
34. Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M and Reich R: Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 10: 7335-7346, 2004. (Pubitemid 39487723)
35. HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions. Clin Biochem 38: 1031-1033, 2005.